Imricor Medical Systems (ASX:IMR) reported an 840% year-on-year surge to AU$255,000 in its consumables revenue for the fourth quarter of 2024, according to a Thursday filing with the Australian bourse.
Total revenue reached AU$280,000, excluding the company's first capital sale in Qatar. The sale will be recognized in future quarters upon installation, per the filing.
Cash and cash equivalents at the end of the fourth quarter stood at $15.7 million.
The medical device maker's shares rose past 3% in recent Friday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。